Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs ONEOK Inc. Common Stock (OKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs ONEOK Inc. Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while ONEOK Inc. Common Stock trades at $91.78 (market cap $58.87B). The key difference: ONEOK Inc. Common Stock is far larger — about 60.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and ONEOK Inc. Common Stock pays a 4.58% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and ONEOK Inc. Common Stock for 5 Days on average.
| MRVI | OKE | |
|---|---|---|
Market Cap | $972.90M | $58.87B |
Volume | 4,325,710 | 2,504,054 |
Sector | Health | Energy |
52-Week High | $9.00 | $97.51 |
52-Week Low | $2.83 | $64.31 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $1.08B | $91.73B |
Dividend Yield | — | 4.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
ONEOK (OKE) trades at $93.38, up 1.48% with a bullish technical outlook and strong fundamental performance. The stock shows solid valuation metrics with P/E of 16.13 and P/S of 1.5, supported by $33.63B revenue and $3.39B net income in 2025. Recent acquisition of Brazos Midstream's assets for $4.425B expands Permian Basin presence, while quarterly dividends remain steady at $1.07 per share.
Outlook remains positive with analyst consensus target of $98.55 (5.5% upside) and no sell ratings. Key risks include integration of recent acquisition and commodity price exposure. Earnings beat expectations in 2 of last 3 quarters, with Q3 2026 results due October 27 providing next catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About ONEOK Inc. Common Stock
ONEOK operates energy infrastructure for natural gas, natural gas liquids, and crude oil. Its assets include pipelines, processing facilities, storage, and related services.
Read more on OKE →
